219 related articles for article (PubMed ID: 4947017)
41. [Immunologic reaction-readiness in malignant melanoma].
Bickhardt R; Kunze J
Z Hautkr; 1974 Apr; 49(8):315-33. PubMed ID: 4599330
[No Abstract] [Full Text] [Related]
42. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
[TBL] [Abstract][Full Text] [Related]
43. [Immunological aspects in malignant melanoma].
Macher E
Arch Dermatol Forsch; 1972; 244():234-9. PubMed ID: 4675197
[No Abstract] [Full Text] [Related]
44. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
[No Abstract] [Full Text] [Related]
45. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
46. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
[TBL] [Abstract][Full Text] [Related]
47. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
48. Self-recognition and tumor response to immunotherapy.
Ernstoff MS
J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939
[No Abstract] [Full Text] [Related]
49. [Active specific immunotherapy of malignant melanoma].
Lotem M; Shiloni E; Ingber A; Peretz T
Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
[No Abstract] [Full Text] [Related]
50. Immunotherapy of melanoma.
Chapman PB
Cancer Chemother Biol Response Modif; 2002; 20():371-83. PubMed ID: 12703215
[No Abstract] [Full Text] [Related]
51. [Cutaneous, cellular immunity in malignant melanoma].
Kehrer HC
Wien Klin Wochenschr; 1991; 103(13):396-7. PubMed ID: 1897233
[No Abstract] [Full Text] [Related]
52. Cellular immunity to human tumor-associated antigens. A review.
Herberman RB
Isr J Med Sci; 1973 Mar; 9(3):300-7. PubMed ID: 4575654
[No Abstract] [Full Text] [Related]
53. Immunological detection of altered signaling molecules involved in melanoma development.
Kawakami Y; Sumimoto H; Fujita T; Matsuzaki Y
Cancer Metastasis Rev; 2005 Jun; 24(2):357-66. PubMed ID: 15986143
[TBL] [Abstract][Full Text] [Related]
54. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.
Haanen JB; Baars A; Gomez R; Weder P; Smits M; de Gruijl TD; von Blomberg BM; Bloemena E; Scheper RJ; van Ham SM; Pinedo HM; van den Eertwegh AJ
Cancer Immunol Immunother; 2006 Apr; 55(4):451-8. PubMed ID: 16034562
[TBL] [Abstract][Full Text] [Related]
55. Interaction of mononuclear leukocytes with malignant melanoma.
Fujinami N; Zucker-Franklin D; Valentine F
Lab Invest; 1981 Jul; 45(1):28-37. PubMed ID: 7253562
[TBL] [Abstract][Full Text] [Related]
56. [Immunology of malignant melanoma. Current data].
Pavie-Fischer J; Kourilsky FM
Rev Prat; 1975 Nov; 25(51):4027-8, 4031-3. PubMed ID: 1209142
[No Abstract] [Full Text] [Related]
57. Immunological studies on malignant melanomas of man.
Romsdahl MM; Cox IS
Yale J Biol Med; 1973 Dec; 46(5):693-701. PubMed ID: 4205125
[No Abstract] [Full Text] [Related]
58. [Value of ultrastructural morphology in the preparation of oncolysates of human malignant melanoma].
Noël P; Faucon M; Leftheriotis E; Fontanière B; Bailly C; Carcagne C; Groleas M; Rezvoy M
Ann Anat Pathol (Paris); 1979; 24(2):125-35. PubMed ID: 525843
[TBL] [Abstract][Full Text] [Related]
59. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
[TBL] [Abstract][Full Text] [Related]
60. Potentiation and arming of lymphocyte mediated immunity by sera from melanoma patients.
Vanwijck R; Bouillenne C; Malek-Mansour S
Eur J Cancer (1965); 1975 Apr; 11(4):267-76. PubMed ID: 1079770
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
